Case Report

A Novel Missense MEN1 Mutation in a Sporadic Case of Multiple Endocrine Neoplasia Type 1 Complicated with Papillary Thyroid Carcinoma

Koji Shibuya, Ken Ebihara, Manabu Takahashi, Tomoyuki Kurashina, Shuichi Nagashima, Kenta Okada, and Shun Ishibashi
Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan

Corresponding author: Ken Ebihara,

DOI: 10.31662/jmaj.2022-0187

Received: October 31, 2022
Accepted: November 25, 2022
Advance Publication: March 6, 2023


Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder, resulting from MEN1 gene abnormalities, which causes tumors mainly in the endocrine glands. We experienced a sporadic case of MEN1 complicated with papillary thyroid carcinoma (PTC) and found a novel missense mutation in the patient’s MEN1 gene. Her older sister, who showed no typical symptom of MEN1, had a history of PTC, suggesting the presence of another genetic factor involved in PTC development. This case suggests the importance of an individual’s genetic background in the development of MEN1 complications.

Key words: MEN1, papillary thyroid carcinoma, missense mutation


Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder that causes tumors mainly in the endocrine glands, including the parathyroid glands, the pancreas, and the pituitary gland. MEN1 can also cause tumors in other endocrine glands, such as the adrenal glands and the thyroid gland. MEN1 is an autosomal dominant disorder caused by MEN1 gene abnormalities. However, about 1 in 10 cases of MEN1 are sporadic. We herein report a sporadic case of MEN1 complicated with papillary thyroid carcinoma (PTC) and a novel missense mutation in the patient’s MEN1 gene.

Case Report

A 29-year-old Japanese woman presented to our department for hypercalcemia. She had an isthmectomy for a median adenomatous goiter 5 years ago. This time, thyroid masses were pointed out again at her workplace health examination. Ultrasonography confirmed a 7-mm mass with border irregularity and sand grain calcification, which was diagnosed as PTC by fine needle aspiration cytology (Figure 1A). This diagnosis was later confirmed in a resection specimen. As hypercalcemia at the level of 12.5 mg/dL was found by a preoperative blood test, she was referred to our department for further examination.

Figure 1. Diagnosis of thyroid tumor and MEN1 by imaging. (A) Ultrasonography of the thyroid gland. (B) 99mTc-MIBI scintigraphy of parathyroid glands. (C) 99mTc-MIBI scintigraphy of the submental region. (D) CT scan of the neck. (E) CT scan of the pancreas. (F) Endoscopic ultrasonography of the pancreas. (G) Enhanced MRI of the pituitary gland. T1 and T2 weighted images (left and right, respectively). Red arrows indicate sites of lesions.

Her intact-parathyroid hormone level was obviously elevated (Table 1). Although her FECa value was low, this was thought to be due to vitamin D deficiency (Table 1) (1). 99mTc-MIBI scintigraphy showed abnormal accumulations in the lower right parathyroid gland and the right submental region (Figure 1B and 1C). Although no parathyroid gland swelling was detected with thyroid ultrasonography, a cervical computed tomography (CT) scan showed a tumor near the right carotid sinus (Figure 1D). Pathology with later surgical resection specimens revealed that the cervical tumor was an ectopic parathyroid adenoma and the lower right parathyroid gland was normal tissue. The cervical tumor was considered to be the lesion responsible for hyperparathyroidism. We conducted screening tests for MEN1. An abdominal CT scan showed a tumor in the pancreas, which was revealed as a pancreatic neuroendocrine tumor (P-NET) by endoscopic ultrasound-fine needle aspiration cytology (Figure 1E and 1F). Magnetic resonance imaging (MRI) of the head revealed a pituitary tumor suspected to be an adenoma (Figure 1G). Based on hormonal testing, both her P-NET and pituitary tumor were considered nonfunctional. Given the above results, the patient was clinically diagnosed with MEN1. At her request, right lobe thyroidectomy and cervical tumor resection were performed.

Table 1. The Patient’s Clinical Findings and Laboratory Data on an Initial Medical Examination.

This case Normal range
SBP/DBP (mmHg) 106/68 130/80
BMI (kg/m2) 19.3 18.5-25
FPG (mg/dL) 85 73-109
ALP (IU/L) 695 106-322
Na (mmol/L) 139 138-145
K (mmol/L) 4.4 3.6-4.8
Ca (mg/dL) 12.5 8.8-10.1
P (mg/dL) 2.2 2.7-4.6
Mg (mg/dL) 2.3 1.7-2.5
FECa (%) 0.67 <1.0
Intact-PTH (pg/mL) 496 10-65
ACTH (pg/mL) 52.1 7.2-63.3
F (μg/dL) 12.1 6.24-18.0
TSH (μU/mL) 1.17 0.45-3.33
FT3 (pg/mL) 2.37 2.11-3.51
FT4 (ng/dL) 1.09 0.84-1.44
GH (ng/mL) 0.7 <2.1
IGF-1 (ng/mL) 188 133-312
PRL (ng/mL) 11.3 3.12-15.39
LH (mIU/mL) 7.6 0.5-68.7
FSH (mIU/mL) 7.3 1.5-20.6
C-peptide (ng/mL) 1.51 1.1-3.3
Insulin (μU/mL) 7.9 <16
Gastrin (pg/mL) 95 <200
Glucagon (pg/mL) 208 70-174
Thyroglobulin (ng/mL) 106 <33.7
25-hydroxyvitamin D (ng/mL) 9.9 >20

We performed gene analysis on the MEN1 gene. Direct sequencing of the coding region disclosed a novel heterozygous G to C mutation at nucleotide 293 in exon 2 (Table 2). This mutation predicts the substitution of arginine by proline at codon 98 (R98P). We could not find any reports of the same mutation but found two mutations with different substitutions at the same site in databases available on the internet. Although there was no information on the clinical significance of one mutation, R98Q reported in ClinVar, the carrier of the other mutation, R98L was diagnosed with MEN1 clinically (Table 2) (2). Furthermore, both analytical tools, Polyphen2 and PROVEAN, predicted that the R98P mutation had a damaging or deleterious impact on the biological function of the MEN1 protein (Table 2). Taken together, we concluded that the R98P mutation was the cause of her MEN1 phenotype. Although we did not perform gene analysis in other family members, none of them showed any typical symptoms of MEN1 including hypercalcemia, although one of her older sisters had a history of thyroidectomy for PTC at the age of 34 years. Thus, she was considered a sporadic case for MEN1 and her MEN1 mutation was de novo.

Table 2. Reported Substitutions of Arginine at Codon 98 of the MEN1 Protein and Their Predictions of Functional Effects.

Nucleotide change (amino acid change) Source PolyPhen2 (Score/prediction) PROVEAN (Score/prediction)
c.293G>C (p.R98P) This case 0.995/probably damaging -4.805/deleterious
c.293G>A (p.R98Q) ClinVar 0.743/possibly damaging -2.341/neutral
c.293G>T (p.R98L) Article (1) 0.966/probably damaging -4.889/deleterious


We reported a sporadic case of MEN1 complicated with PTC. MEN1 mutation can cause thyroid tumors. The complication rates of thyroid tumors with MEN1 vary in reports, ranging from 2.6% to 25% (3). When limited to PTC, the complication rate was reported to be 4.7% in one study (4). On the other hand, one of the older sisters of this patient who showed no typical symptoms of MEN1 had a history of PTC, suggesting the presence of another genetic factor involved in the development of PTC; however, the involvement of the MEN1 mutation in the pathogenesis of PTC cannot be denied.

We also reported a novel missense mutation in exon2 of the MEN1 gene. This might be a de novo mutation as this case was sporadic. MEN1 mutations reported so far are distributed across the entire coding region, including exon2 without a hot spot (5). In contrast to MEN2, MEN1 has no obvious genotype-phenotype relationship (6). MEN1 symptoms can differ from person to person, even among family members who have the same MEN1 mutation. These facts indicate that an individual’s genetic background plays an important role in the development of MEN1 complications. In this case, genetic factors involved in the pathogenesis of PTC in the patient and her older sister might affect her MEN1 complications.

In conclusion, we experienced a sporadic case of MEN1 complicated with PTC and found a novel missense mutation in the patient’s MEN1 gene. This case suggests the importance of an individual’s genetic background in the development of MEN1 complications.

Article Information

Conflicts of Interest


Author Contributions

KS was involved in the evaluation and management of the patient. KS and KE did the literature search and drafted the manuscript. MT, TK, SN, KO, and SI revised the manuscript critically. All the authors declare that they contributed to this article and that they read and approved the final version.

Informed Consent

The patient signed informed consent regarding publishing this case in an academic journal.


  1. 1.

    Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115-25.

  2. 2.

    Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat. 2002;20(1):35-47.

  3. 3.

    Capraru OM, Decaussin-Petrucci M, Joly MO, et al. Expression of menin in the human thyroid gland. Acta Endocrinol (Buchar). 2017;13(2):154-60.

  4. 4.

    Yoshimoto K, Saito S. Clinical characteristics in multiple endocrine neoplasia type 1 in Japan: a review of 106 patients. Folia Endocrinologica Japonica. 1991;67(7):764-74. Japanese.

  5. 5.

    Tsukada T, Nagamura Y, Ohkura N. MEN1 gene and its mutations: basic and clinical implications. Cancer Sci. 2009;100(2):209-15.

  6. 6.

    Mele C, Mencarelli M, Caputo M, et al. Phenotypes associated with MEN1 syndrome: a focus on genotype-phenotype correlations. Front Endocrinol (Lausanne). 2020;11:591501.